PMCB (PharmaCyte Biotech) Marketable Securities: $0.37 Mil (As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
30 GF Score
Price $0.70
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Marketable Securities?

PharmaCyte Biotech PMCB -0.50% 30 Marketable Securities is $0.37 Mil as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. PharmaCyte Biotech's Marketable Securities for the quarter that ended in Jan. 2026 was $0.37 Mil.

PharmaCyte Biotech's annual Marketable Securities stayed the same from Apr. 2023 ($0.00 Mil) to Apr. 2024 ($0.00 Mil) but then increased from Apr. 2024 ($0.00 Mil) to Apr. 2025 ($0.37 Mil).

PharmaCyte Biotech  (NAS:PMCB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

PharmaCyte Biotech Marketable Securities Related Terms

PharmaCyte Biotech Marketable Securities Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Marketable Securities Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.37

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.37 0.26 0.20 0.37
PMCB
30GF Score
PharmaCyte Biotech Inc PMCB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.37 Mil mean?
PharmaCyte Biotech (PMCB) has a Marketable Securities of $0.37 Mil as of Jan. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Marketable Securities too high?
PharmaCyte Biotech's current Marketable Securities is $0.37 Mil. Overall, PharmaCyte Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Marketable Securities compare to ERNA and SYBX?
PharmaCyte Biotech's Marketable Securities of $0.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Marketable Securities is $0.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Marketable Securities of $0.37 Mil. The current Marketable Securities is $0.37 Mil. PharmaCyte Biotech's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Marketable Securities is $0.37 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
30GF Score

Get the complete analysis for PMCB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price